Table 5. Summary of fold increase in CD8 T cell recognition of EBV-antigens presented by shBILF1-LCLs compared to shControl-LCLs.

					Fold increase
Expression phase of target antigen	Target antigen	Epitope	HLA restriction	Number of experiments*	Range	Median
IE	BRLF1	YVL	A2	10	<1–2.5	1.9
IE	BZLF1	DPY	B7	4	1.2–1.8	1.7
E	BMLF1	GLC	A2	8	7–11	9.1
E	BMRF1	TLD	A2	5	3.2–10	6
E	BNLF2b	RPG	B7	4	4.5–7	6
L	BALF4	FLD	A2	8	10–25	13.5
L	BNRF1	WQW	A2	4	5.7–16	12.2
L	BNRF1	YPR	B7	4	9–23	11.3

* more than one effector clone specific for each epitope was used where possible. In total, six different donor LCLs were used.